The place of antiplatelet drugs in clinical medicine has been firmly established by experience with aspirin. Antiplatelet Trialists' Collaboration demonstrated that some antiplatelet therapy offers worthwile protection against myocardial infarction, stroke and death. Significant benefit is evident also among many other categories of high risk patients (such as those having vascular procedures and those with unstable angina or peripheral vascular disease). More potent platelet inhibitors have been developed and the challenge of the coming years is if they can be used practically and safety at effective doses in humans. Large scale randomized trials are now ongoing to provide reliable data on secondary prevention of vascular and cerebrovascular events of new interesting drugs.
|Translated title of the contribution||Physiology and nosography of antiplatelet drug|
|Number of pages||5|
|Journal||Giornale di Gerontologia|
|Publication status||Published - 1995|
ASJC Scopus subject areas
- Geriatrics and Gerontology